Last reviewed · How we verify
Inahled Isoflurane
Inhaled isoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory signaling in the central nervous system to produce anesthesia.
Inhaled isoflurane is a volatile anesthetic that enhances inhibitory neurotransmission and suppresses excitatory signaling in the central nervous system to produce anesthesia. Used for General anesthesia for surgical procedures, Maintenance of anesthesia during surgery.
At a glance
| Generic name | Inahled Isoflurane |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Volatile anesthetic |
| Target | GABA-A receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Isoflurane potentiates GABA-A receptor activity and inhibits NMDA glutamate receptors, leading to depression of the central nervous system. This results in loss of consciousness, analgesia, and muscle relaxation suitable for surgical anesthesia. The drug is administered via inhalation and has a rapid onset and offset due to its volatile nature.
Approved indications
- General anesthesia for surgical procedures
- Maintenance of anesthesia during surgery
Common side effects
- Postoperative nausea and vomiting
- Respiratory depression
- Hypotension
- Bradycardia
- Hepatotoxicity (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inahled Isoflurane CI brief — competitive landscape report
- Inahled Isoflurane updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI